Stewart, S., Ekman, I., Ekman, T., Oden, A. & Rosengren, A. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ. Cardiovasc. Qual. Outcomes 3, 573–580 (2010).

Article  PubMed  Google Scholar 

Bozkurt, B. et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J. Card. Fail. 27, 387–413 (2021).

Article  Google Scholar 

Tsao, C. W. et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation 147, e93–e621 (2023).

Article  PubMed  Google Scholar 

Bozkurt, B. Heart failure epidemiology and outcomes statistics. J. Card. Fail. 29, 1412–1451 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Vasan, R. S., Enserro, D. M., Beiser, A. S. & Xanthakis, V. Lifetime risk of heart failure among participants in the Framingham study. J. Am. Coll. Cardiol. 79, 250–263 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, e263–e421 (2022).

Article  PubMed  Google Scholar 

Siddiqi, T. J. et al. Trends in heart failure-related mortality among older adults in the United States from 1999-2019. JACC Heart Fail. 10, 851–859 (2022).

Article  PubMed  Google Scholar 

Jain, V. et al. Demographic and regional trends of heart failure-related mortality in young adults in the US, 1999-2019. JAMA Cardiol. 7, 900–904 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Bozkurt, B. et al. Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF. JACC Heart Fail. 11, 1320–1332 (2023).

Article  PubMed  Google Scholar 

Bozkurt, B. It is time to screen for heart failure: why and how? JACC Heart Fail. 10, 598–600 (2022).

Article  PubMed  Google Scholar 

McDonagh, T. A. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599–3726 (2021).

Article  CAS  PubMed  Google Scholar 

Del Gobbo, L. C. et al. Contribution of major lifestyle risk factors for incident heart failure in older adults: the cardiovascular health study. JACC Heart Fail. 3, 520–528 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Hu, G., Jousilahti, P., Antikainen, R., Katzmarzyk, P. T. & Tuomilehto, J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation 121, 237–244 (2010).

Article  PubMed  Google Scholar 

Uijl, A. et al. Risk for heart failure: the opportunity for prevention with the American Heart Association’s Life’s Simple 7. JACC Heart Fail. 7, 637–647 (2019).

Article  PubMed  Google Scholar 

Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).

Article  CAS  PubMed  Google Scholar 

Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

Article  CAS  PubMed  Google Scholar 

Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).

Article  CAS  PubMed  Google Scholar 

Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 373, 11–22 (2015).

Article  PubMed  Google Scholar 

Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marso, S. P. et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J. Am. Coll. Cardiol. 75, 1128–1141 (2020).

Article  CAS  PubMed  Google Scholar 

Jorsal, A. et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) — a multicentre, double-blind, randomised, placebo-controlled trial. Eur. J. Heart Fail. 19, 69–77 (2017).

Article  CAS  PubMed  Google Scholar 

Margulies, K. B. et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316, 500–508 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamad, F. et al. Systematic review of glucagon-like peptide one receptor agonist liraglutide of subjects with heart failure with reduced left ventricular ejection fraction. Curr. Diabetes Rev. 17, 280–292 (2021).

Article  PubMed  Google Scholar 

Lingvay, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31, 111–122 (2023).

Article  CAS  PubMed  Google Scholar 

Novo Nordisk A/S. Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial. Press release 8 August 2023. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301 (2023).

Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).

Article  CAS  PubMed  Google Scholar 

Ledwidge, M. et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310, 66–74 (2013).

Article  CAS  PubMed  Google Scholar 

Pop-Busui, R. et al. Heart failure: an underappreciated complication of diabetes. a consensus report of the american diabetes association. Diabetes Care 45, 1670–1690 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Pfeffer, M. A. et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N. Engl. J. Med. 385, 1845–1855 (2021).

Article  CAS  PubMed  Google Scholar 

Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022).

Article  PubMed  Google Scholar 

Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).

Article  CAS  PubMed  Google Scholar 

Udell, J. A. et al. Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC review topic of the week. J. Am. Coll. Cardiol. 79, 2058–2068 (2022).

Article  CAS  PubMed  Google Scholar 

Bozkurt, B. Pre-heart failure: an important opportunity to prevent a deadly disease. JACC Heart Fail. 11, 1027–1031 (2023).

Article  PubMed  Google Scholar 

Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

Article  CAS  PubMed  Google Scholar 

Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

Article  CAS  PubMed  Google Scholar 

Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).

Article  CAS  PubMed  Google Scholar 

Marx, N. et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 44, 4043–4140 (2023).

Article  CAS  PubMed  Google Scholar 

Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).

Article  CAS  PubMed  Google Scholar 

Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).

Article  CAS  PubMed  Google Scholar 

Filippatos, G. et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145, 437–447 (2022).